For Moderate to Severe Vasomotor Symptoms
Ligand Scores on FDA Approval of Pfizer’s Hot Flash Drug Duavee
By Marie Powers
Friday, October 4, 2013
Ligand Pharmaceuticals Inc. scored the first direct hit from its decades-long collaboration with Pfizer Inc. as the FDA approved Duavee (conjugated estrogens/bazedoxifene) in a once-daily 0.45-mg/20-mg tablet form.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.